Increased level of acute phase reactants in patients infected with modern <i>Mycobacterium tuberculosis </i>genotypes in Mwanza, Tanzania by Stavrum, Ruth et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Increased level of acute phase reactants in patients infected with modern
Mycobacterium tuberculosis genotypes in Mwanza, Tanzania
Stavrum, Ruth; PrayGod, George; Range, Nyagosya; Faurholt-Jepsen, Daniel; Jeremiah,
Kidola; Faurholt-Jepsen, Maria; Krarup, Henrik; Aabye, Martine G; Changalucha, John; Friis,
Henrik; Andersen, Aase B; Grewal, Harleen M S
Published in:
B M C Infectious Diseases
DOI:
10.1186/1471-2334-14-309
Publication date:
2014
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Stavrum, R., PrayGod, G., Range, N., Faurholt-Jepsen, D., Jeremiah, K., Faurholt-Jepsen, M., ... Grewal, H. M.
S. (2014). Increased level of acute phase reactants in patients infected with modern Mycobacterium tuberculosis
genotypes in Mwanza, Tanzania. B M C Infectious Diseases, 14, [309]. https://doi.org/10.1186/1471-2334-14-
309
Download date: 03. Feb. 2020
Stavrum et al. BMC Infectious Diseases 2014, 14:309
http://www.biomedcentral.com/1471-2334/14/309RESEARCH ARTICLE Open AccessIncreased level of acute phase reactants in
patients infected with modern Mycobacterium
tuberculosis genotypes in Mwanza, Tanzania
Ruth Stavrum1*, George PrayGod2, Nyagosya Range3, Daniel Faurholt-Jepsen4, Kidola Jeremiah2,
Maria Faurholt-Jepsen4, Henrik Krarup5, Martine G Aabye6, John Changalucha2, Henrik Friis4, Aase B Andersen7
and Harleen MS Grewal1,8Abstract
Background: There is increasing evidence to suggest that different Mycobacterium tuberculosis lineages cause
variations in the clinical presentation of tuberculosis (TB). Certain M. tuberculosis genotypes/lineages have been
shown to be more likely to cause active TB in human populations from a distinct genetic ancestry. This study
describes the genetic biodiversity of M. tuberculosis genotypes in Mwanza city, Tanzania and the clinical
presentation of the disease caused by isolates of different lineages.
Methods: Two-hundred-fifty-two isolates from pulmonary TB patients in Mwanza, Tanzania were characterized by
spoligotyping, and 45 isolates were further characterized by mycobacterium interspersed repetitive unit-variable
number tandem repeat (MIRU-VNTR). The patients’ level of the acute phase reactants AGP, CRP and neutrophil
counts, in addition to BMI, were measured and compared to the M. tuberculosis lineage of the infectious agent for
each patient.
Results: The most frequent genotype was ST59 (48 out of 248 [19.4%]), belonging to the Euro-American
lineage LAM11_ZWE, followed by ST21 (CAS_KILI lineage [44 out of 248 [17.7%]). A low degree of diversity
(15.7% [39 different ST’s out of 248 isolates]) of genotypes, in addition to a high level of mixed M. tuberculosis
sub-populations among isolates with an unreported spoligotype pattern (10 out of 20 isolates [50.0%]) and isolates
belonging to the ST53 lineage (13 out of 25 [52%]) was observed. Isolates of the ‘modern’ (TbD1-) Euro-American
lineage induced higher levels of α1-acid glycoprotein (β = 0.4, P = 0.02; 95% CI [0.06-0.66]) and neutrophil counts
(β = 0.9, P = 0.02; 95% CI [0.12-1.64]) and had lower BMI score (β = −1.0, P = 0.04; 95% CI[−1.89 – (−0.03)]). LAM11_ZWE
(‘modern’) isolates induced higher levels of CRP (β = 24.4, P = 0.05; 95% CI[0.24-48.63]) and neutrophil counts (β = 0.9,
P = 0.03; 95% CI[0.09-1.70]).
Conclusion: The low diversity of genotypes may be explained by an evolutionary advantage of the most common
lineages over other lineages combined with optimal conditions for transmission, such as overcrowding and inadequate
ventilation. The induction of higher levels of acute phase reactants in patients infected by ‘modern’ lineage isolates
compared to ‘ancient’ lineages may suggest increased virulence among ‘modern’ lineage isolates.* Correspondence: Ruth.Stavrum@gades.uib.no
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Genotyping of Mycobacterium tuberculosis, the causative
agent of TB, may be utilized in order to study TB transmis-
sion dynamics, differentiate between possible outbreaks and
laboratory cross-contamination, detect mixed infections
and to evaluate the effectiveness of a TB control program
by differentiating between relapse and re-infection.
Although the members of the M. tuberculosis Complex
show a high degree of sequence similarity at the genome
level [1] the combination of different forms of genotyping
such as Single Nucleotide Sequencing (SNP) and Large
Sequence Polymorphisms (LSP) have shown that some
lineages are associated with increased transmissibility,
whereas others induce stronger host inflammatory re-
sponses [2]. The pathogenicity of an organism is determined
by the organism’s virulence factors, which is described
as the severity of disease caused by that organism, or
the pathogens infectivity. Certain genotypes/lineages
of M. tuberculosis are more likely to cause active TB
in human populations from a distinct genetic ancestry
[3,4] suggesting an adaptation by the pathogen to its
human host. One lineage in particular, the W/Beijing
lineage, has been studied extensively over many years due
to its hypervirulence and increased level of multi-drug
resistance. However, a recent study by Hanekom et al. [5]
showed that this lineage in fact consists of 7 sub-lineages,
where one sub-lineage shows increased resistance to
anti-TB drugs, whereas another sub-lineage shows an
increased level of transmissibility. This finding shows how
differences among the infectious agents may impact their
ability to cause infection and disease among their hosts.
TB has been shown to be associated with significant
alterations in the levels of many serum proteins [6].
Acute phase reactants are proteins produce in the liver
in response to an inflammation. The acute phase reactant
C-reactive protein (CRP) is an established marker of acute
inflammation [7], whereas the acute phase reactant
α1-acid glycoprotein (AGP) has previously been associated
with active TB [8] and latent TB [9].
Till date, there are no studies describing the distribution
and frequency of the different genotypes of M. tuberculosis
in Mwanza, Tanzania. As of 2012, the United Republic of
Tanzania ranked 16 on the list of the 22 high-tuberculosis
(TB) burden countries in the world [10]. Out of 909 cases
which were tested in Tanzania for MDR-TB in 2009, 16
(1.8%) had MDR-TB, out of which 11 (68.8%) were new
cases and 5 (31.2%) were previously treated patients [11]. If
untreated, it has been shown that one smear-positive TB
patient can infect up to 15 other people over the course of
one year [12,13] highlighting the urgent need for rapid
detection and adequate anti-TB treatment. Thus, the
primary objective of this study was to genotypically
characterize M. tuberculosis isolates collected from
sputum smear-positive pulmonary TB patients in thecity of Mwanza, using the well-established genotyping
methods, spoligotyping and MIRU-VNTR. With the
growing evidence that the genetic diversity among the
M. tuberculosis genotypes/lineages may be an important
factor with regards to clinical presentation, severity of
disease and outcome of infection [14,15], the secondary
objective included exploring differences in clinical presen-
tation of TB disease and to determine whether any of
these differences could be associated with the lineage of
the infecting isolates.
Methods
Patient enrolment
This study was conducted in Mwanza city, in northwestern
Tanzania. It is the second largest city in Tanzania. The city
occupies the surface area of 1,325 sq kms, and according
to 2002 census it had a population of about 500,000 [16].
Patients aged >15 years recruited at the local health
facilities and confirmed as sputum culture positive at the
Zonal TB Reference Laboratory were included in the study.
Pregnant women, patients with terminal illness (from TB
or any other serious disease unlikely to survive more than
48 h), non-residents (patients who would not stay in the
study area for the entire period of 6 months of anti-TB
treatment) and patients not willing to participate were not
considered for enrolment. Patients diagnosed as sputum
smear positive by microscopy using Ziehl-Neelsen (ZN)
staining at the first visit to a diagnostic health facility were
referred to any of the four main recruitment health
facilities. Those who consented and for whom one or both
spot and next day early morning sputum samples were ZN
smear microscopy positive were requested to provide
an additional early morning sputum specimen. Smear
microscopy examination was performed using Auramine
O staining and culture using Lowenstein-Jensen (LJ)
solid media.
Data collection
Following informed consent, information on the partici-
pants was collected using structured questionnaires at the
first visit before initiation of anti-TB treatment. Venous
blood (15 ml) was drawn from each participant for HIV
testing, total lymphocyte count and CD4 cell counts. All
M. tuberculosis isolates used in this study were collected
from sputum smear positive pulmonary TB patients
attending three of the major health clinics in Mwanza
city from April 2006 –November 2008, according to WHO
guidelines.
Study sample
A total of 842 patients met the study criteria and were thus,
included in this cohort. Information on data collection
and laboratory procedures has been described in detail
previously [17]. Serum concentrations of the acute phase
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(AGP) were determined at the Department of Clinical
Biochemistry, Aalborg University Hospital, Denmark.
Serum CRP was reported in mg/L and serum AGP in
g/L with a lowest detection limit at 10 mg/L and
0.4 g/L, respectively. Serum levels of CRP >10 mg/L
and AGP >1.2 g/L were reported as elevated. Weight and
height were measured with the participant barefooted and
with minimal clothing to the nearest 0.1 kg and 0.1 cm,
respectively. The body mass index (BMI) was calculated
as weight/height2 [kg/m2] [18]. Drug susceptibility testing
(DST) was performed at the National Institute for Medical
Research Laboratory, Mwanza, Tanzania for the 4 first line
drugs isoniazid (H), rifampicin (R), streptomycin (SM)
and ethambutol (E) according to the World Health
Organization (WHO) recommendations.
Ethics statement
Ethical permission was obtained from the Medical Research
Coordinating committee of the National Institute for
Medical Research (NIMR) in Tanzania, and consultative
approval was given by The Danish National Committee on
Biomedical Research Ethics. Written and oral information
was presented to all eligible participants by the health staff
before written informed consent was obtained. Written
consent was obtained from parents/legal guardians of any
participants under 18 years of age. Counseling prior to
HIV-testing was compulsory, and post-test counseling was
offered to all who tested HIV-positive. Participants
with diagnosed HIV and/or diabetes were referred to the
respective clinics for care and management.DNA isolation
Two-hundred-fifty-two M. tuberculosis isolates, which
were available for this study, were sub-cultured on
Löwenstein Jensen solid media at 37°C for 3–8 weeks
and DNA was isolated using a boiling technique,
where a 1 μl loop-full of bacterial cells were sus-
pended in 200 μl of TE-buffer (10 mM Tris-Cl,
1 mM EDTA) and heat-killed by incubation at 95°C
for 15–20 min [19]. The supernatant containing the
DNA was collected by centrifugation at 12 000 rpm for
7 min. If heat extraction yielded DNA of poor quality
causing difficulties for genotyping genomic DNA was
isolated as previously described by van Embden [20].Spoligotyping
Spoligotyping was performed on genomic DNA by using
the standard method as previously described [21].
Based on their spoligotype pattern, the isolates were
assigned to families based on previously described
criteria [22,23].MIRU-VNTR
Certain spoligotypes are more prone to be the product
of admixing, thus creating a false spoligotype pattern
[24]. A previous study conducted in South Africa [25]
showed that 54% of isolates identified, by spoligotyping as
belonging to the ST53 genotype, were comprised of mixed
M. tuberculosis sub-populations. Thus, isolates belonging
to the ST53 and ST451 (H37Rv) genotypes in addition
to isolates with a previously unreported spoligopattern
(according to the SITVIT database; http://www.pasteur-
guadeloupe.fr:8081/SITVIT_ONLINE/), were chosen for
MIRU-VNTR genotyping by amplification of 24 loci as
described by Supply et al. [26] in order to rule out wrong-
ful characterization due to mixed infections. Amplification
was performed in a total volume of 20 μl containing 1 μl
DNA, 0.04 to 0.4 μM of all 24 primer sets, and HotStart
Taq Plus polymerase Master Mix (Qiagen). All reaction
mixtures were subjected to 95°C for 5 min; 30 cycles of
30 s at 94°C, 1 min at 55°C, and 1.5 min at 72°C; and
7 min at 72°C. Analysis of the genotyping results was per-
formed by multiplex PCR with a LIZ-1200 size standard
(PE Applied Biosystems) for sizing of the PCR products.
The PCR fragments were analyzed with a capillary-based
electrophoresis sequencer (ABI 3730), and sizing of
the various VNTR alleles was done with the Gene
Mapper v/4.1 (PE Applied Biosystems). The number
of repeats present at each locus was determined, and
alleles were assigned numerical values accordingly.
Isolates with 100% identical MIRU-VNTR genotypes
were defined as belonging to the same cluster.
Statistical analyses
In exploratory analysis, linear and logistic regression
models were used to test the association of M. tuberculosis
lineages (Tables 1 and 2) with various background and
clinical parameters. The models were adjusted for age, sex
and HIV. Serum AGP was analyzed stratified by HIV
status due to interactions (p < 0.05) between HIV and
lineage groups with respect to AGP as a response. The
data were assessed in three steps; comparing modern
(TbD1-) against ancient (TbD1+) lineages, comparing EAI
and Euro-American (Gagneux), respectively, against
Indo-Oceanic (ancient), as well as comparing the most com-
mon modern spoligotypes, CAS_KILI and LAM11_ZWE,
against the most common ancient spoligotype, EAI5. The
models were compiled in Stata 12 (StataCorp LP, Texas).Results
Spoligotyping
Out of 252 isolates characterized by spoligotyping, 4 iso-
lates gave a blank result whereas 248 isolates produced a
spoligopattern. Background characteristics for the 248
isolates included in this study are presented in Table 1.
Table 1 Background characteristics of 248 patients
included in this study
Variables No. of patients (n = 248)
Age range (mean) 15-81 (52)
Gender
Male 150
Female 98
Diabetes
Yes 6
No 241
Unknown 1
HIV
Positive 95
Negative 153
Previously treated
Yes 20
No 225
Unknown 3
TB-contact
Yes 77
No 170
Unknown 1
Smoking
Yes 53
No 195
BCG scar
Yes 201
No 46
Unknown 1
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previously described shared-types [STs] [23] belonging to
4 previously defined lineages [23]. The Euro-American
lineage (comprising the lineages as defined by Brudey [23]
was the most common M. tuberculosis lineage. Out of
135 Euro-American lineage isolates, 125 isolates were
assigned to 21 different STs (Table 2). The most fre-
quent genotype was ST59 (n = 48 [19.4%]), belonging
to the Euro-American lineage LAM11_ZWE, followed
by ST21 (CAS_KILI lineage) comprising n = 44 out of 248
(17.7%) isolates (Table 2). Out of the 248 isolates which
were subjected to spoligotyping, n = 20 (8.1%) isolates did
not match with any of the previously described spoligo
patterns [23] and thus, were not assigned to any of the
previously defined STs (Table 2). The 20 isolates with pre-
viously un-described octal codes were assigned to lineages
according to the web-based algorithm SPOTCLUST [27].
Out of 20 new isolates, 10 belonged to the Indo-Oceanic
(CAS; n = 7 [35.0%], EAI2; n = 1 [5.0%], EAI4; n = 1[5.0%], and EAI5; n = 1 [5.0%]) lineage and n = 10 isolates
belonged to the Euro-American (T1; n = 6 [30%],
F33; n = 2 [10.0%], LAM8; n = 1 [5.0%], and H1; n = 1
[5.0%]) lineage (Table 2). The spoligopattern and octal code
for these 20 newly described isolates are given in Table 3.
MIRU-VNTR
Fifty-one isolates; 25 belonging to the ST53 genotype,
and 20 isolates with previously unassigned spoligotypes
were subjected to analysis by MIRU-VNTR for the
purpose of identifying mixed Mycobacterium infections.
Furthermore, as H37Rv is a laboratory strain, the pres-
ence of 6 isolates belonging to the ST451 (H37Rv)
lineage was considered a laboratory contamination. This
was confirmed by MIRU-VNTR. Out of the 45 ST53
and unreported spoligotypes analyzed by MIRU-VNTR,
22 samples consisted of a single M. tuberculosis sub-
population (Table 4), whereas 10 out of the 20 (50%)
unassigned isolates and 13 out of 25 (52%) ST53 geno-
types were of mixed Mycobacterium sub-populations
(i.e. harbored ≥2 alleles for ≥2 loci). The 24-loci
MIRU-VNTR code for the 12 ST53 isolates and the 10 un-
assigned isolates, which were of a single sub-population,
are provided in Table 4. Six isolates (samples 58 and
228; 38 and 46, and 94 and 242) formed 3 clusters
(100% identical MIRU-VNTR code), comprising two
isolates each (Table 4). There was no correlation between
the occurrence of mixed infections and gender (odds ratio
[OR], 0.55; 95% confidence interval [CI], 0.12-2.45;
P = 0.29), HIV-status (OR, 0.77; 95% CI, 0.19-3.04,
P = 0.45), or having a previous history of TB-infection
(OR, 0.45; 95% CI, 0.15-7.24, P = 0.48).
hsp65 sequencing
Four isolates which did not produce a spoligo pattern,
were subjected to sequencing of the hsp65 gene and
compared to the NCBI database (BLASTN). One of the
isolates showed a 100% match with the Mycobacterium
fortuitum lineage, whereas the other 3 isolates matched
100% with the M. tuberculosis complex.
Drug susceptibility testing (DST)
Out of the 248 isolates with a valid spoligotyping result
DST was performed on 244 isolates. The DST showed
that 231 isolates (94.7%) were sensitive to all four
first-line anti-TB drugs, 13 were found to be resistant
to any of the 4 first-line drugs (H: n = 7, SM: n = 2,
H/SM: n = 2, H/SM/E: n = 1, H/E: n = 1), including 1
multi-drug resistant isolate (resistant to both rifampicin
and isoniazid in addition to streptomycin and etambuthol).
Nine of the 13 resistant isolates belonged the Euro
American lineage (LAM11_ZWE [n = 4], T3 [n = 2], H1,
[n = 1], LAM9 [n = 1], and H37Rv [n = 1]. Four isolates
belonged to the East African (CAS_KILI [n = 4]) lineage.
Table 2 Overview of circulating lineages/genotypes in Mwanza, Tanzania and background characteristics of the infected patients
Gagneux
lineage
Brudey
lineage
Shared-
type
District Sex TB history Previous TB treatment HIV-
infected
Buzuruga
HC (n = 93)
Sekou Toure regional
Hospital (n = 104)
Bugando medical
centre (n = 51)
Female
(n = 98)
Male
(n = 150)
Unknown
(n = 3)
New
(n = 233)
Relapse
(n = 12)
Unknown
(n = 3)
No
(n = 225)
Yes
(20)
No
(153)
Yes
(95)
East African-
Indian
CAS Unassigned 2 2 3 2 5 1 6 0 0 7 0 4 3
CAS_KILI ST21 17 16 11 18 26 0 42 2 0 40 4 25 19
CAS1_DELHI ST26 4 8 3 4 11 0 15 0 0 15 0 10 5
CAS2 ST288 2 0 0 1 1 0 2 0 0 2 0 2 0
East Asian BEIJING ST1 0 1 2 2 1 0 3 0 0 2 1 2 1
Euro-
American
F33 Unassigned 2 0 0 2 0 0 2 0 0 2 0 2 0
H1 Unassigned 0 1 0 0 1 0 1 0 0 1 0 1 0
ST218 4 3 0 4 3 0 7 0 0 5 2 5 2
H3 ST50 1 2 1 3 1 0 4 0 0 4 0 2 2
H37Rv ST451 2 1 3 3 3 0 6 0 1 5 0 3 3
LAM1 ST20 0 1 0 0 1 0 1 0 0 1 0 1 0
LAM10_CAM ST61 0 1 1 1 1 0 2 0 0 1 1 0 2
LAM11_ZWE ST1607 0 1 0 1 0 0 1 0 0 1 0 1 0
ST1873 1 0 1 1 1 0 2 0 0 2 0 1 1
ST59 21 19 8 25 23 0 45 3 1 44 3 32 16
LAM4 ST811 1 0 1 1 1 0 2 0 0 2 0 1 1
LAM8 Unassigned 1 0 0 0 1 0 1 0 0 1 0 0 1
LAM9 ST42 2 4 0 2 4 0 6 0 0 5 1 4 2
T1 Unassigned 3 3 0 1 5 0 6 0 0 6 0 5 1
ST102 2 1 0 0 3 0 3 0 0 3 0 2 1
ST1122 0 1 0 0 1 0 0 1 0 0 1 0 1
ST373 0 2 0 0 2 0 2 0 0 1 1 0 2
ST53 7 13 5 7 18 1 21 3 1 21 3 14 11
ST612 0 1 0 1 0 0 1 0 0 1 0 1 0
T2 ST135 0 1 1 1 1 0 2 0 0 2 0 1 1
ST420 2 0 2 1 3 0 3 1 0 4 0 4 0
ST52 0 0 1 0 1 0 1 0 0 1 0 0 1
T3 ST37 1 3 0 1 3 1 3 0 0 4 0 4 0
T3_ETH ST149 0 2 0 2 0 0 2 0 0 2 0 0 2
U ST1570 0 0 1 1 0 0 0 1 0 0 1 0 1
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Indo-Oceanic EAI2 Unassigned 1 0 0 1 0 0 1 0 0 1 0 0 1
EAI4 Unassigned 0 1 0 0 1 0 1 0 0 1 0 1 0
EAI5 Unassigned 1 0 0 0 1 0 1 0 0 1 0 1 0
ST126 12 11 6 6 23 0 29 0 0 28 1 17 12
ST1369 1 1 0 1 1 0 2 0 0 2 0 2 0
ST924 1 0 0 1 0 0 1 0 0 1 0 1 0
EAI5 or EAI3 ST8 2 4 1 4 3 0 6 1 0 6 1 4 3
Table 2 Overview of circulating lineages/genotypes in Mwanza, Tanzania and background characteristics of the infected patients
Gagneux
lineage
Brudey
lineage
Shared-
type
District Sex TB history Previous TB treatment HIV-
infected
Buzuruga
HC (n = 93)
Sekou Toure regional
Hospital (n = 104)
Bugando medical
centre (n = 51)
Female
(n = 98)
Male
(n = 150)
Unknown
(n = 3)
New
(n = 233)
Relapse
(n = 12)
Unknown
(n = 3)
No
(n = 225)
Yes
(20)
No
(153)
Yes
(95)
(Continued)
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Table 3 M. tuberculosis isolates with previously unreported spoligopatterns identified in this study
ID Octal code Brudey lineage1 Gagneux lineage2 Mwanza urban district MIRU-VNTR
7 777777606063771 F33 Euro-American Buzuruga HC Mixed
149 777777747763771 F33 Euro-American Buzuruga HC Mixed
120 777777744020731 H1 Euro-American Sekou Toure regional Hospital Single
262 777777606061771 LAM8 Euro-American Buzuruga HC Mixed
122 747777777760730 T1 Euro-American Sekou Toure regional Hospital Single
160 777615647760771 T1 Euro-American Buzuruga HC Mixed
107 777737777760730 T1 Euro-American Buzuruga HC Single
224 777747777760771 T1 Euro-American Sekou Toure regional Hospital Single
183 777777477761771 T1 Euro-American Buzuruga HC Mixed
129 777777777721771 T1 Euro-American Sekou Toure regional Hospital Mixed
88 703377400001671 CAS Indo-Oceanic Buzuruga HC Single
238 703377400003771 CAS Indo-Oceanic Sekou Toure regional Hospital Single
26 703377740001771 CAS Indo-Oceanic Bugando Medical Centre Mixed
202 703377740001771 CAS Indo-Oceanic Sekou Toure regional Hospital Mixed
169 703777400003771 CAS Indo-Oceanic Bugando Medical Centre Mixed
172 703777600000171 CAS Indo-Oceanic Bugando Medical Centre Single
265 703777700000771 CAS Indo-Oceanic Buzuruga HC Mixed
236 777000007413371 EAI2 Indo-Oceanic Buzuruga HC Single
29 777777740003231 EAI4 Indo-Oceanic Sekou Toure regional Hospital Single
132 777741757413771 EAI5 Indo-Oceanic Buzuruga HC Single
1 Lineages defined by Gagneux et al. [23].
2 Lineages defined by Brudey et al. [22].
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lineage.
Comparison between groups/lineages
The logistic regression analyses showed that among HIV
negative patients levels of AGP was higher (β = 0.3, P =
0.05; 95% CI [0.005 – 0.59]) in patients infected with a
‘modern’ (TbD1-) M. tuberculosis strain as compared to
patients infected with isolates belonging to the ‘ancient’
(TbD1+) reference group (Table 5, left model).
Patients infected with isolates belonging to the Euro-
American lineage (‘modern’) had lower BMI score (β =
−1.0, P = 0.04; 95% CI [−1.89 – (−0.03)]) in addition to
higher levels of AGP (β = 0.4, P = 0.02; 95% CI [0.06-
0.66]) and neutrophil count (β = 0.9, P = 0.02; 95% CI
[0.12-1.64]), as compared to the Indo-Oceanic (‘ancient’)
reference group. Patients infected with isolates belonging
to the East-African Indian lineage (‘modern’) did not re-
spond significantly different from patients infected with
isolates belonging to the Indo-Oceanic lineage for any of
the variables tested (Table 5, right model).
When comparing the largest family of isolates within
each of the lineages defined by Gagneux et al. [22]
LAM11_ZWE (‘modern’) induced a higher level of CRP
(β = 24.4, P = 0.05; 95% CI [0.24-48.63]) and neutrophil
count (β = 0.9, P = 0.03; 95% CI [0.09-1.70]) ascompared to patients infected with isolates belonging to
the ‘ancient’ EAI5 family reference group (Table 6). The
level of AGP was also elevated among the patients in-
fected with LAM11-ZWE isolates, however, this increase
was not statistically significant (β = 0.4, P = 0.06; [−0.01-
0.73]), possibly due to a low sample size. Patients in-
fected with isolates belonging to the ‘modern’ CAS_KILI
did not respond differently from patients infected with
isolates belonging to the ‘ancient’ EAI5 family (Table 6).
Adjustment for bacterial load (the number of colonies)
did not affect the estimates (data not shown), also we
found no associations between being infected with a
‘modern’ lineage isolate and having diabetes, smoking,
TB contact and the presence of a BCG scar.
Discussion
Few studies [28,29] have reported on the frequency of
circulating genotypes in Tanzania as determined by spo-
ligotyping. The current study indicates that 4M. tuber-
culosis genotypes are responsible for ~55% of all TB
cases in Mwanza City, Tanzania.
The genetic biodiversity of M. tuberculosis for a par-
ticular area can be attributed to, amongst others, geog-
raphy and demography, and the level of human
migration, travels, immigration and trade [28]. In this
study, two genotypes, ST21 and ST59, belonging to the
Table 4 24-loci MIRU-VNTR codes of isolates belonging to the ST53 genotype and isolates with previously unreported spoligopatterns
Mix 1 Mix 2 Mix 3 Mix 4
580 2996 802 960 1644 3192 424 577 2165 3690 4156
Sample Shared-type MIRU 04 MIRU 026 MIRU 40 MIRU 10 MIRU 16 MIRU 31 VNTR 42 VNTR 43 AVNTR ETR-A VNTR 52 VNTR 53
21 ST53 2 5 2 3 4 3 2 4 2 3 *
38 ST53 2 1 2 4 1 2 1 4 3 3 4
46 ST53 2 1 2 4 1 2 1 4 3 3 4
56 ST53 2 1 2 4 1 3 1 4 3 3 4
58 ST53 2 1 2 4 1 2 1 4 3 3 4
94 ST53 2 5 4 3 1 3 2 4 3 3 3
136 ST53 2 5 * 3 1 3 2 4 2 7 3
166 ST53 2 1 2 * 1 3 1 4 3 4 4
228 ST53 2 1 2 4 1 2 1 4 3 3 4
237 ST53 2 1 4 5 1 3 4 2 3 3 *
242 ST53 2 5 4 3 1 3 2 4 3 3 *
249 ST53 2 1 2 4 1 3 1 4 3 3 *
29 Unassigned 2 2 4 4 4 5 1 2 9 5 2
88 Unassigned 2 1 4 7 4 4 4 2 4 2 *
107 Unassigned 2 4 3 3 3 4 2 5 4 3 3
120 Unassigned 2 4 3 3 3 4 2 5 4 4 4
122 Unassigned 2 5 3 3 3 3 2 3 3 3 3
132 Unassigned 2 2 2 4 2 5 2 4 7 2 2
172 Unassigned 2 1\7 4 4 6 6 4 2 4 2 4
224 Unassigned 2 5 4 1 2 3 2 4 3 3 3
236 Unassigned 4 2 3 4 3 4 2 4 9 4 2
238 Unassigned 2 1 4 7 4 4 4 2 3 2 *
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Table 4 24-loci MIRU-VNTR codes of isolates belonging to the ST53 genotype and isolates with previously unreported spoligopatterns
Mix 5 Mix 6 Mix 7 Mix 8
2163b 1955 4052 154 2531 4348 2059 2687 3007 2347 2461 3171
ple VNTR QUB11b VNTR 1955 VNTR QUB-26 MIRU 02 MIRU 23 MIRU 39 MIRU 20 MIRU 24 MIRU 27 VNTR 46 VNTR 48 VNTR 49
1 4 2 4 2 5 2 2 1 3 4 2 3
8 2 3 7 2 5 2 1 1 3 4 2 3
6 2 3 7 2 5 2 1 1 3 4 2 3
6 2 3 7 2 5 2 2 1 3 4 2 3
8 2 3 7 2 5 2 1 1 3 4 2 3
4 4 2 * 2 3 2 2 1 3 3 2 3
6 2 2 * 2 5 2 2 1 3 4 3 3
6 1 3 * 2 5 2 2 1 3 4 2 3
8 2 3 7 2 5 2 1 1 3 4 2 3
7 2 3 3 2 5 2 2 1 3 4 2 3
2 4 2 2 2 3 2 2 1 3 3 2 3
9 2 3 5 2 5 2 2 1 3 4 2 3
9 9 6 6 2 6 3 2 2 3 3 4 3
8 2 3 4 2 5 3 2 1 3 4 2 3
7 2 3 7 2 5 2 1 1 3 4 1 0\3
0 2 3 7 2 1 2 2 1 3 4 1 3
2 2 3 7 2 5 2 1 1 3 2 2 3
2 7 8 5 2 6 2 2 2 3 3 5 3
2 2 4 4 2 5 1 2 1 2 4 2 3
4 4 3 5 2 5 2 1 1 3 4 3 3
6 6 6 5 2 4 3 2 2 3 3 3 3
8 2 3 5 2 5 3 2 1 3 4 2 3
where a PCR product could not be produced are marked with ‘*’.
(Continued)
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Table 5 Associations between infection by ‘ancient’ and ‘modern’ M. tuberculosis sublineages (according to Gagneux et al. [22]) and clinical manifestations
Groups Reference group: ‘Ancient’ (n = 42) Reference group: Indo-Oceanic (n = 42)
‘Modern’ (n = 183) EAI (n = 64) Euro-American (116)
Variables Regression coefficient 95% CI P-value Regression coefficient 95% CI P-value Regression coefficient 95% CI P-value
Age (years)1 −0.6 [−4.80 – 3.68] 0.80 1.0 [−3.89 – 5.93] 0.68 −1.4 [−5.84 – 3.11] 0.55
Weight (kg/m2)2 −2.0 [−1.63 – 0.16] 0.11 −1.7 [−4.82 – 1.42] 0.29 −2.4 [−5.25 – 0.44] 0.1
BMI (kg/m2)2 −0.7 [−1.63 – 0.16] 0.11 −0.5 [−1.52 – 0.52] 0.33 −1.0 [−1.89 - -0.03] 0.05
CRP (mg/L)2 14.2 [−4.20 – 32.52] 0.13 8.0 [−13.18 – 29.21] 0.46 18.5 [−0.85 – 37.76] 0.06
AGP (g/L)1* 0.3 [0.005 – 0.59] 0.053 0.2 [−0.11 – 0.55] 0.19 0.4 [0.06 – 0.66] 0.02
Neutrophil count (x 109 cells/L)2 0.6 [−0.13 – 1.32] 0.11 0.1 [−0.71 – 0.96] 0.77 0.9 [0.12 – 1.64] 0.02
Lymphocyte count (x 109 cells/L)2 0.2 [−0.16 – 0.49] 0.32 0.3 [−0.08 – 0.67] 0.12 0.1 [−0.26 – 0.42] 0.65
CD4 count (cells/ul)2 −21.2 [−122.66 – 80.36] 0.68 21.9 [−95.47 – 139.35] 0.71 −45.9 [−152.95 – 61.19] 0.40
Hemoglobin (g/dl)2 0.03 [−0.68 – 0.75] 0.93 0.3 [−0.50 – 1.15] 0.44 −0.2 −0.91 – 0.59 0.67
Fasting blood glucose (mmol/L)2 0.1 [−0.32 – 0.51] 0.65 −0.02 [−0.48 – 0.45] 0.95 0.1 [1.71 – 5.08] 0.59
Diabetes (Yes)2 1.5 [0.55 – 4.24] 0.42 1.2¶ [0.35 – 3.75] 0.81 1.7¶ [0.60 – 4.97] 0.27
Smoking (Yes)2 2.6 [0.32 – 20.81] 0.38 1.5¶ [0.54 – 3.97] 0.46 0.9¶ [0.32 – 2.23] 0.74
TB contact (Yes)2 1.3 0.59 – 2.70 0.55 0.2¶ [0.50 – 2.90] 0.67 1.2¶ [0.56 – 2.76] 0.59
BCG scar2 1.5 [0.63 – 3.32] 0.39 1.1¶ [0.43 – 2.83] 0.83 1.7¶ [0.69 – 4.13] 0.25
Results are based on a linear and logistic regression models adjusted for age, sex and HIV status.
1Adjusted for HIV status and gender
2Adjusted for HIV status, age and gender
3P-values <0.05 are in bold.
*HIV negative only
¶Odds ratio
BMI: Body Mass Index.
EAI: East-African Indian.
CRP: C-reactive protein.
AGP: Orosomucoid.
BCG: Bacillus Calmette-Guerrin.
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Table 6 Associations between infection by different M. tuberculosis sublineages (according to the SpolDB4 [23]) and
clinical manifestations
Groups Reference group: EAI5 (n = 33)
CAS_KILI (n = 44) LAM11_ZWE (n = 51)
Variables Regression coefficient 95% CI P-value Regression coefficient 95% CI P-value
Age (years)1 1.8 [−4.55 – 8.06] 0.58 −0.6 [−6.84 – 5.68] 0.86
Weight (kg/m2)2 −1.0 [−4.37 – 2.48] 0.59 −3.0 [−6.39 – 0.40] 0.08
BMI (kg/m2)2 −0.5 [−1.62 – 0.67] 0.41 −0.9 [−2.07 – 0.19] 0.10
CRP (mg/L)2 13.2 [−11.26 – 37.66] 0.29 24.4 [0.24 – 48.63] 0.05
AGP (g/L)1* 0.2 [−0.15 – 0.62] 0.23 0.4 [−0.01 – 0,73] 0.06
Neutrophil count (x 109 cells/L)2 −0.1 [−0.93 – 0.69] 0.77 0.9 [0.09 – 1.70] 0.03
Lymphocyte count(x 109 cells/L)2 0.4 [−0.02 – 0.91] 0.06 0.3 [−0.18 – 0.74] 0.23
CD4 count (cells/ul)2 38.8 [−91.88 – 169.46] 0.56 −13.0 [−142.54 – 116.53] 0.84
Hemoglobin (g/dl)2 0.1 [−0.90 – 1.12] 0.83 −0.4 [−1.40 – 0.60] 0.43
Fasting blood glucose (mmol/L)2 −0.1 [−0.52 – 0.30] 0.60 −0.3 [−0.68 – 0.14] 0.19
Diabetes2 1.3 [0.35 – 4.99] 0.68 1.1 [0.28 – 4.22] 0.89
Smoking2 1.4 [0.44 – 4.22] 0.60 1.3¶ [0.41 – 4.19] 0.64
TB contact2 1.1 [0.39 – 3.12] 0.85 1.3¶ [0.46 – 3.44] 0.66
BCG scar2 1.2 [0.40 – 3.51] 0.76 1.5¶ [0.51 – 4.60] 0.44
Results are based on a linear and logistic regression models adjusted for age, sex and HIV status.
1Adjusted for HIV status and gender.
2Adjusted for HIV status, age and gender.
3P-values <0.05 are in bold.
*HIV negative only.
¶Odds ratio.
BMI: Body Mass Index.
EAI: East-African Indian.
CRP: C-reactive protein.
AGP: Orosomucoid.
BCG: Bacillus Calmette-Guerrin.
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comprised 37% of the 248 isolates analyzed. The pre-
dominance of these two families in the northern part
of Tanzania has been demonstrated previously [23,28]
and may suggest a biological advantage for these lineages in
this region. CAS_KILI and LAM11_ZWE lineages are con-
sidered to belong to the ‘modern’ (TbD1-) M. tuberculosis
lineages and are regarded as more recently evolved than
the more ‘ancient’ EAI5 lineage. Interestingly, this study
shows that isolates belonging to the more ‘modern’
Euro-American lineage induced higher levels of the
acute phase response and neutrophil counts. Combined
with a reduction of the BMI in patients infected with
‘modern’ lineage isolates, this finding suggest that
‘modern’ lineages induce an increased level of acute
phase responses than isolates belonging to the more
‘ancient’ Indo-Oceanic lineage. However, the data presented
for this study are cross-sectional limiting any interpretation
of causality. Still, we found that the most abundant lineage,
the ‘modern' Euro-American, was associated with a higher
acute phase response as well as a higher leukocyte count.
The high prevalence combined with more severe clinical
manifestations indicate that the ‘modern' Euro-Americanlineage may be more virulent and, thus, more susceptible
to transmission in this population compared to the ‘ancient’
and the ‘modern' East-African Indian lineages. It has
previously been shown that more recent and evolutionary
successful isolates of the Beijing family of strains elicit a
lower cytokine response than the Euro-American linage
[30]. As stated above; an organism’s virulence factors, is
described as the severity of disease caused by that organ-
ism, or the pathogens infectivity. Thus, the virulence and
infectivity of an organism cannot be explained only by its
ability to induce a strong host response, as other factors
such as the dynamic interaction between the host and the
pathogen plays an important role in determining the
outcome of the infection. Furthermore, this supports our
findings that there are differences among the ‘modern’
families with regards to the degree of inflammation
they cause. When comparing the two most common
‘modern’ families identified for this study (CAS_KILI
and LAM11_ZWE) to the most common ‘ancient’
family (EAI5), this study showed that among the
‘modern’ families, there are differences in the level of
acute phase responses caused by the two families.
Whereas the CAS_KILI isolates induced similar levels
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LAM11_ZWE isolates induced a higher acute phase
response in addition to higher neutrophil counts. As the
presence of a visible BCG scar has been shown to have an
effect on the sputum conversion at 2 months post anti-TB
treatment [17] a possible linkage between the lineage of
the infecting isolate and the presence of a visible BCG scar
was investigated. No such correlation was observed.
The relatively low diversity of different genotypes
in Mwanza City (15.7%) observed for this study, as
compared to Dar es Salaam [52% [29]], is suggestive
of a high degree of ongoing transmission of the most
frequent genotypes, indicating an evolutionary advantage
of the most common lineages over the other lineages
combined with optimal conditions for transmission, such
as an urban setting with overcrowding and inadequate
ventilation. The Beijing lineage, a highly virulent genotype
which is associated with high transmission and a high
level of multi-drug resistance [4], was found at a very low
frequency in the Mwanza city. The frequency (1.2%) of
isolates belonging to the Beijing lineage observed in this
study is low compared to a previous study [28] performed
on isolates collected from northern Tanzania where the
Beijing lineage was reported to be the 5th most frequent
genotype. The low number of Beijing lineage isolates
may contribute towards the very low number of multidrug-
resistant isolates observed for this study. Furthermore,
the very high frequency (95%) of isolates being sensi-
tive to the four first-line anti-TB drugs is suggestive
of a well-functioning treatment strategy.
Another cause for concern was the high number (51%)
of mixed M. tuberculosis sub-populations observed in
the isolates which were selected for MIRU-VNTR
analysis. The presence of mixed M. tuberculosis sub-
population among isolates belonging to the ST53
lineage has been demonstrated previously [25] and
may be explained by the cumulative presence of
spacers in all strains present, creating a ‘false’ ST53
pattern [24,25,31]. Multiple infections by different
strains of M. tuberculosis are more likely to occur in
high TB-endemic settings where the infection pressure
is high. The true implications of a high level of mixed
infections in a population is not clear however, it has
been shown previously [32] that a mixed infection
may be responsible for a change in drug-resistance
pattern during treatment, and possibly may accelerate the
emergence of multi-drug resistant isolates. As described
by Lazzarini et al. [24], some spoligotype patterns are
more likely than others to be the result of a mixed infec-
tion. Thus, in order to find the true frequency of the most
dominating strains in Mwanza, further characterization,
by MIRU-VNTR, would need to be performed for a larger
selection of isolates belonging to the most dominating
genotypes.Conclusion
The findings from this study indicate that ‘modern’ lineage
isolates appear more virulent generally inflicting higher
severity of the disease than ‘ancient’ lineage isolates.
The low diversity of genotypes may be explained by an
evolutionary advantage of the most common lineages
over the other lineages combined with optimal conditions
for transmission, such as overcrowding and inadequate
ventilation. Ultimately, this may lead to increased transmis-
sion and spread of the ‘modern’ lineages in this area.
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